S6K1 inhibition has been suggested as a new therapeutic target to improve glucose disposal in obese patients, with one study demonstrating that S6K KO mice fed with a high-fat diet (HFD) were protected against diet-induced obesity, whereas S6K KO mice were still insulin sensitive [181]. The gene discussed is RPS6KB1; the disease is obesity due to melanocortin 4 receptor deficiency.